GENE ONLINE|News &
Eli Lilly, Lycia Partnership Signifies the Growing Targeted Protein Degradation Market
On August 25th, South San Francisco-based startup Lycia Therapeutics entered a multi-year collaboration with Eli Lilly to discover, develop and commercialize novel targeted therapeutics using the former's proprietary protein degradation technology.
As per the agreement, Lilly will pay Lycia $35 million in an upfront payment. In addition, Lycia is also eligible to receive over $1.6 billion in potential milestone payments as well as tiered royalties from mid-single to low double-digits on sales.
As per the agreement, Lilly will pay Lycia $35 million in an upfront payment. In addition, Lycia is also eligible to receive over $1.6 billion in potential milestone payments as well as tiered royalties from mid-single to low double-digits on sales.
GO Prime with only $1.49 now
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
